Innate Pharma has been selected for oral presentation “Excellent non clinical safety profile of IPH4102, the first anti-KIR3DL2 mAb for the treatment of CTCL” during Session 7 at the T-cell Lymphoma Forum Parc 55, Windham San Francisco, CA https://www.tcellforum.com/ Poster: Excellent non clinical safety profile of IPH4102, the first anti-KIR3DL2 mAbfor the treatment of CTCL 160.66 KB Date Thu, 01/29/2015 - 08:30
